Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lucid DiagnosticsLUCD +1.47%14 Days Sales Outstanding is 48.39 as of Mar. 2026, which is 81% above its 10-year median of 26.68. GuruFocus rates LUCD with a GF Score™ of 14/100 and a GF Value™ of $0.83 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 810 Medical Devices & Instruments companies, Lucid Diagnostics ranks better than 90.37% on this metric.
The historical rank and industry rank for Lucid Diagnostics's Days Sales Outstanding or its related term are showing as below:
LUCD'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.78 Med: 26.68 Max: 146
Current: 32.93
During the past 7 years, Lucid Diagnostics's highest Days Sales Outstanding was 146.00. The lowest was 3.78. And the median was 26.68.
LUCD's Days Sales Outstanding is ranked better than 90.37% of 810
companies
in the Medical Devices & Instruments industry
Industry Median: 66.35
vs LUCD: 32.93
Lucid Diagnostics's Days Sales Outstanding
increased
from Mar. 2025 (5.84) to Mar. 2026 (48.39).
Lucid Diagnostics (NAS:LUCD) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Lucid Diagnostics Days Sales Outstanding Related Terms
Lucid Diagnostics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Lucid Diagnostics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LUCD vs QTRX, QSI, INGN: Days Sales Outstanding Comparison
For the Medical Devices subindustry, Lucid Diagnostics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lucid Diagnostics Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Lucid Diagnostics's Days Sales Outstanding falls into.
Lucid Diagnostics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lucid Diagnostics (LUCD) has a Days Sales Outstanding of 48.39 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Lucid Diagnostics and its competitors. This is 81% above median its historical median of 26.68. Over the past decade, Lucid Diagnostics' Days Sales Outstanding has ranged from 3.78 to 146.00. According to the industry distribution chart, Lucid Diagnostics ranks #78 out of 810 companies in the Medical Devices & Instruments industry, placing it in the top 9.6%.
Is Lucid Diagnostics' Days Sales Outstanding too high?
Lucid Diagnostics' current Days Sales Outstanding of 48.39 is 81% above median its 10-year median of 26.68. Over the past 10 years, this metric has ranged from a low of 3.78 to a high of 146.00. The Medical Devices & Instruments industry median Days Sales Outstanding is 66.35. Lucid Diagnostics' value of 48.39 is 27.1% below this industry median. Based on the distribution chart, Lucid Diagnostics ranks #78 out of 810 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Lucid Diagnostics has a GF Score™ of 14/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lucid Diagnostics' Days Sales Outstanding compare to QTRX and QSI?
According to the Medical Devices & Instruments industry distribution chart, Lucid Diagnostics ranks #78 out of 810 companies for Days Sales Outstanding. This places Lucid Diagnostics in the top 10% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 66.35. Lucid Diagnostics' value of 48.39 is 27.1% below this benchmark. Historically, Lucid Diagnostics' own Days Sales Outstanding has ranged from 3.78 to 146.00 over the past decade. While the company's 10-year median is 26.68 vs. the industry median of 66.35, Lucid Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 66.35, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lucid Diagnostics's current Days Sales Outstanding of 48.39 is 27.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Lucid Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 66.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lucid Diagnostics's current Days Sales Outstanding is 48.39, which is 81% above median its own 10-year median of 26.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucid Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Lucid Diagnostics (LUCD) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.83, compared to a current price of $0.97 — trading 16.7% above its estimated fair value. The current Days Sales Outstanding is 48.39, which is 81% above median its 10-year median of 26.68 and 27.1% below the Medical Devices & Instruments industry median of 66.35. Lucid Diagnostics' overall GF Score™ is 14/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Lucid Diagnostics (LUCD), the current Days Sales Outstanding is 48.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lucid Diagnostics (LUCD) Overvalued in 2026?
Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued.
The current stock price of $0.97 is trading 16.7% above its estimated GF Value™ of $0.83.
GuruFocus considers Lucid Diagnostics to be Modestly Overvalued.
Key valuation signals for LUCD:
Days Sales Outstanding: 48.39 (81% above median its 10-year median of 26.68)
GF Value™: $0.83 vs. price of $0.97 (16.7% above fair value)
Industry Position: 27.1% below the Medical Devices & Instruments median (#78 of 810)
No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
14GF Score
Get the complete analysis for LUCD
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUCD has been successfully added to your 
